HIF2{alpha} Antagonism Has Antitumor Activity in Advanced ccRCC [Clinical Trials]

The HIF2α antagonist PT2385 achieved responses in 14% of patients with heavily pretreated ccRCC.

from Cancer via ola Kala on Inoreader http://ift.tt/2nMBTHY
via IFTTT